HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael R Verneris Selected Research

tisagenlecleucel

12/2022Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
1/2022Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
1/2022Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
12/2021Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia.
11/2021Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
1/2021Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.
1/2018Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael R Verneris Research Topics

Disease

28Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
12/2022 - 06/2008
27Leukemia
01/2022 - 03/2009
24Graft vs Host Disease (Graft-Versus-Host Disease)
11/2021 - 06/2007
22Neoplasms (Cancer)
01/2021 - 01/2003
19Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/2021 - 06/2007
13Hematologic Neoplasms (Hematological Malignancy)
12/2022 - 11/2010
11Infections
01/2021 - 07/2005
8Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2021 - 06/2007
6Residual Neoplasm
01/2021 - 06/2012
4Inflammation (Inflammations)
12/2019 - 03/2014
3Myeloid Leukemia (Leukemia, Myelocytic)
01/2018 - 06/2007
3Fever (Fevers)
12/2016 - 09/2014
2Cytokine Release Syndrome
01/2022 - 01/2018
2Sarcoma (Soft Tissue Sarcoma)
01/2020 - 02/2018
2BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2018 - 06/2007
2Human Influenza (Influenza)
01/2017 - 01/2013
2Metabolic Syndrome (Dysmetabolic Syndrome X)
12/2016 - 01/2016
2Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive)
11/2016 - 01/2010
2Myeloproliferative Disorders (Myeloproliferative Disorder)
10/2016 - 03/2012
2Obesity
01/2016 - 02/2009
2Neutropenia
10/2015 - 09/2014
2Lymphoma (Lymphomas)
12/2012 - 01/2003
2Philadelphia Chromosome
06/2012 - 12/2009
1Juvenile Myelomonocytic Leukemia
11/2021
1Chickenpox
01/2021
1Measles
01/2021
1Melanoma (Melanoma, Malignant)
01/2021
1Mumps
01/2021
1Autoimmune Hemolytic Anemia (Cold Agglutinin Disease)
01/2020
1Cytopenia
01/2020
1Agammaglobulinemia (Hypogammaglobulinemia)
01/2020
1Central Nervous System Neoplasms
10/2019
1Primary Immunodeficiency Diseases
01/2019
1HIV Infections (HIV Infection)
05/2018

Drug/Important Bio-Agent (IBA)

7Chimeric Antigen ReceptorsIBA
12/2022 - 01/2018
7tisagenlecleucelIBA
12/2022 - 01/2018
6LigandsIBA
11/2021 - 06/2007
5CytokinesIBA
01/2021 - 12/2012
4EndoglinIBA
10/2020 - 06/2015
4AntigensIBA
10/2018 - 01/2016
3Immunoglobulins (Immunoglobulin)IBA
11/2021 - 01/2020
3Glucose (Dextrose)FDA LinkGeneric
11/2020 - 01/2016
3Proteins (Proteins, Gene)FDA Link
10/2018 - 06/2014
3Cyclosporine (Ciclosporin)FDA LinkGeneric
01/2018 - 09/2007
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2022 - 07/2013
2fludarabineIBA
12/2022 - 01/2018
2blinatumomabIBA
12/2021 - 01/2019
2Intravenous Immunoglobulins (IVIG)FDA Link
01/2021 - 01/2020
2Polysaccharides (Glycans)IBA
01/2021 - 04/2012
2carotuximabIBA
10/2020 - 01/2017
2Transforming Growth Factors (Transforming Growth Factor)IBA
10/2020 - 01/2017
2Monoclonal AntibodiesIBA
10/2020 - 01/2017
2KIR ReceptorsIBA
01/2020 - 05/2010
2FollistatinIBA
01/2020 - 06/2015
2Biomarkers (Surrogate Marker)IBA
12/2019 - 02/2009
2Biological ProductsIBA
01/2019 - 05/2013
2HLA-A Antigens (HLA-A)IBA
01/2019 - 10/2016
2LeptinIBA
01/2019 - 06/2015
2Epidermal Growth Factor (EGF)IBA
02/2018 - 06/2015
2Mycophenolic Acid (Cellcept)FDA LinkGeneric
01/2018 - 11/2016
2DNA (Deoxyribonucleic Acid)IBA
09/2014 - 05/2013
2Interleukin-2 (IL2)IBA
06/2014 - 12/2005
2ChemokinesIBA
03/2014 - 12/2012
2Messenger RNA (mRNA)IBA
02/2014 - 04/2012
2HLA Antigens (Human Leukocyte Antigens)IBA
11/2010 - 11/2009
1CD19-specific chimeric antigen receptorIBA
01/2022
1Isoantigens (Alloantigen)IBA
10/2021
1Immunoglobulin G (IgG)IBA
01/2021
1Immune Checkpoint InhibitorsIBA
01/2021
1VaccinesIBA
01/2021
1CD19 AntigensIBA
01/2021
1CXC ChemokinesIBA
01/2021
1Reactive Oxygen Species (Oxygen Radicals)IBA
10/2020
1Rituximab (Mabthera)FDA Link
01/2020
1daratumumabIBA
01/2020
1SteroidsIBA
12/2019
1Interferon Type IIBA
12/2019
1DioxygenasesIBA
01/2019
1Interleukin-2 Receptors (IL 2 Receptor)IBA
01/2019
1AdipokinesIBA
01/2019
1AdiponectinIBA
01/2019
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2019
1Surface Antigens (Surface Antigen)IBA
10/2018
1ErbB Receptors (EGF Receptor)IBA
02/2018
1Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
02/2018
1Membrane Proteins (Integral Membrane Proteins)IBA
02/2018
1Immunotoxins (Immunotoxin)IBA
02/2018
1Urokinase Plasminogen Activator ReceptorsIBA
02/2018
1treosulfanIBA
01/2018

Therapy/Procedure

35Cell Transplantation
11/2021 - 07/2005
26Transplantation
11/2021 - 03/2009
22Therapeutics
01/2022 - 01/2003
14Drug Therapy (Chemotherapy)
12/2022 - 01/2003
6Immunotherapy
01/2022 - 12/2005
6Hematopoietic Stem Cell Transplantation
12/2019 - 05/2011
3Homologous Transplantation
01/2020 - 03/2009
2Stem Cell Transplantation
10/2019 - 01/2017
1Glycemic Control
11/2020
1Critical Care (Surgical Intensive Care)
11/2020
1Aftercare (After-Treatment)
02/2018